Compare Stocks: PLRX, RNAC, ALXO, and TRDA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALXO ALX Oncology	$2.03 -2.4%	$2.03	$0.99 ▼ $2.66	$287.62M	0.39	1.15 million shs	603,416 shs
PLRX Pliant Therapeutics	$1.13 -2.6%	$1.11	$1.02 ▼ $1.95	$71.83M	1.27	456,963 shs	299,286 shs
RNAC Cartesian Therapeutics	$9.12 +0.4%	$9.07	$5.60 ▼ $11.00	$274.72M	0.62	114,687 shs	134,913 shs
TRDA Entrada Therapeutics	$7.17 -1.8%	$7.08	$5.02 ▼ $16.45	$284.24M	-0.25	255,201 shs	395,559 shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALXO ALX Oncology	-2.40%	-0.98%	+3.05%	+31.82%	+99.02%
PLRX Pliant Therapeutics	-2.59%	-1.74%	+7.62%	-1.74%	-33.92%
RNAC Cartesian Therapeutics	+0.44%	-8.53%	+13.15%	+56.16%	-11.02%
TRDA Entrada Therapeutics	-1.78%	-1.38%	-0.97%	+12.56%	+34.77%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALXO ALX Oncology	$2.03 -2.4%	$2.03	$0.99 ▼ $2.66	$287.62M	0.39	1.15 million shs	603,416 shs
PLRX Pliant Therapeutics	$1.13 -2.6%	$1.11	$1.02 ▼ $1.95	$71.83M	1.27	456,963 shs	299,286 shs
RNAC Cartesian Therapeutics	$9.12 +0.4%	$9.07	$5.60 ▼ $11.00	$274.72M	0.62	114,687 shs	134,913 shs
TRDA Entrada Therapeutics	$7.17 -1.8%	$7.08	$5.02 ▼ $16.45	$284.24M	-0.25	255,201 shs	395,559 shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALXO ALX Oncology	-2.40%	-0.98%	+3.05%	+31.82%	+99.02%
PLRX Pliant Therapeutics	-2.59%	-1.74%	+7.62%	-1.74%	-33.92%
RNAC Cartesian Therapeutics	+0.44%	-8.53%	+13.15%	+56.16%	-11.02%
TRDA Entrada Therapeutics	-1.78%	-1.38%	-0.97%	+12.56%	+34.77%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALXO ALX Oncology	2.67	Moderate Buy	$4.60	126.60% Upside
PLRX Pliant Therapeutics	1.75	Reduce	$3.00	165.49% Upside
RNAC Cartesian Therapeutics	2.57	Moderate Buy	$32.60	257.46% Upside
TRDA Entrada Therapeutics	2.50	Moderate Buy	$17.75	147.56% Upside

Current Analyst Ratings Breakdown

Latest PLRX, RNAC, ALXO, and TRDA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/31/2026	TRDA Entrada Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/19/2026	ALXO ALX Oncology	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/18/2026	RNAC Cartesian Therapeutics	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$38.00
8/13/2026	TRDA Entrada Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/12/2026	TRDA Entrada Therapeutics	Roth Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$11.00
8/5/2026	ALXO ALX Oncology	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/29/2026	RNAC Cartesian Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
7/17/2026	PLRX Pliant Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
6/30/2026	RNAC Cartesian Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
6/26/2026	ALXO ALX Oncology	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
6/12/2026	RNAC Cartesian Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)

(Data available from 9/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALXO ALX Oncology	N/A	N/A	N/A	N/A	$0.98 per share	N/A
PLRX Pliant Therapeutics	$1.58M	44.28	N/A	N/A	$2.37 per share	0.48
RNAC Cartesian Therapeutics	$2.80M	98.53	N/A	N/A	($4.14) per share	-2.20
TRDA Entrada Therapeutics	$25.42M	10.98	N/A	N/A	$5.99 per share	1.20

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALXO ALX Oncology	-$101.69M	-$1.13	N/A	N/A	N/A	N/A	-90.30%	-67.28%	11/6/2026 (Estimated)
PLRX Pliant Therapeutics	-$149.34M	-$1.49	N/A	N/A	N/A	N/A	-52.17%	-40.46%	11/5/2026 (Estimated)
RNAC Cartesian Therapeutics	-$130.30M	-$5.94	N/A	N/A	N/A	-8,550.65%	N/A	-29.84%	11/5/2026 (Estimated)
TRDA Entrada Therapeutics	-$143.75M	-$3.96	N/A	N/A	N/A	-3,537.73%	-57.61%	-46.54%	11/5/2026 (Estimated)

Latest PLRX, RNAC, ALXO, and TRDA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2026	Q2 2026	PLRX Pliant Therapeutics	-$0.3418	-$0.36	-$0.0182	-$0.36	N/A	N/A
8/6/2026	Q2 2026	ALXO ALX Oncology	-$0.1429	-$0.13	+$0.0129	-$0.13	N/A	N/A
8/6/2026	Q2 2026	RNAC Cartesian Therapeutics	-$0.8779	$0.46	+$1.3379	$0.46	$0.18 million	N/A
8/5/2026	Q2 2026	TRDA Entrada Therapeutics	-$0.9738	-$1.01	-$0.0363	-$1.01	$2.32 million	$0.90 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALXO ALX Oncology	N/A	N/A	N/A	N/A	N/A
PLRX Pliant Therapeutics	N/A	N/A	N/A	N/A	N/A
RNAC Cartesian Therapeutics	N/A	N/A	N/A	N/A	N/A
TRDA Entrada Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALXO ALX Oncology	0.07	9.71	9.71
PLRX Pliant Therapeutics	N/A	9.90	9.90
RNAC Cartesian Therapeutics	N/A	7.48	7.48
TRDA Entrada Therapeutics	N/A	10.89	10.89

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALXO ALX Oncology	97.97%
PLRX Pliant Therapeutics	97.30%
RNAC Cartesian Therapeutics	86.95%
TRDA Entrada Therapeutics	86.39%

Insider Ownership

Company	Insider Ownership
ALXO ALX Oncology	12.40%
PLRX Pliant Therapeutics	8.74%
RNAC Cartesian Therapeutics	37.20%
TRDA Entrada Therapeutics	9.49%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALXO ALX Oncology	40	138.28 million	121.13 million	Optionable
PLRX Pliant Therapeutics	90	61.92 million	56.51 million	Optionable
RNAC Cartesian Therapeutics	64	30.25 million	19.00 million	Optionable
TRDA Entrada Therapeutics	110	38.94 million	35.24 million	Optionable

PLRX, RNAC, ALXO, and TRDA Headlines

Recent News About These Companies

Entrada Therapeutics (NASDAQ:TRDA) Major Shareholder Sells $180,691.89 in Stock

September 3 at 9:12 PM | marketbeat.com

Insider Selling: Entrada Therapeutics (NASDAQ:TRDA) Major Shareholder Sells $205,361.28 in Stock

September 3 at 9:12 PM | marketbeat.com

Entrada Therapeutics (NASDAQ:TRDA) Major Shareholder Bioventures 2018 L.P. Mpm Sells 32,263 Shares of Stock

September 3 at 9:12 PM | marketbeat.com

Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 2 at 4:30 PM | globenewswire.com

Insider Selling: Entrada Therapeutics (NASDAQ:TRDA) Major Shareholder Sells $26,168.33 in Stock

September 1 at 4:51 AM | insidertrades.com

Insider Selling: Entrada Therapeutics (NASDAQ:TRDA) Major Shareholder Sells $26,168.33 in Stock

August 31, 2026 | marketbeat.com

Entrada Therapeutics (NASDAQ:TRDA) Major Shareholder Bioventures 2018 L.P. Mpm Sells 38,922 Shares

August 31, 2026 | marketbeat.com

Bioventures 2018 L.P. Mpm Sells 44,259 Shares of Entrada Therapeutics (NASDAQ:TRDA) Stock

August 31, 2026 | marketbeat.com

300,575 Shares in Entrada Therapeutics, Inc. $TRDA Bought by Nantahala Capital Management LLC

August 29, 2026 | marketbeat.com

Entrada Therapeutics, Inc. (NASDAQ:TRDA) Given Consensus Rating of "Moderate Buy" by Brokerages

August 29, 2026 | marketbeat.com

Insider Selling: Entrada Therapeutics (NASDAQ:TRDA) Major Shareholder Sells $102,857.14 in Stock

August 27, 2026 | insidertrades.com

Insider Selling: Entrada Therapeutics (NASDAQ:TRDA) Major Shareholder Sells 14,569 Shares of Stock

August 26, 2026 | marketbeat.com

Bioventures 2014 L.P. Mpm Sells 21,623 Shares of Entrada Therapeutics (NASDAQ:TRDA) Stock

August 26, 2026 | marketbeat.com

Bioventures 2014 L.P. Mpm Sells 26,522 Shares of Entrada Therapeutics (NASDAQ:TRDA) Stock

August 26, 2026 | marketbeat.com

5AM Venture Management LLC Acquires Shares of 4,056,379 Entrada Therapeutics, Inc. $TRDA

August 26, 2026 | marketbeat.com

HC Wainwright Analysts Lower Earnings Estimates for TRDA

August 12, 2026 | marketbeat.com

Entrada Therapeutics (NASDAQ:TRDA) Major Shareholder Ventures L.P. 5Am Sells 10,494 Shares of Stock

August 11, 2026 | insidertrades.com

Insider Selling: Entrada Therapeutics (NASDAQ:TRDA) Director Sells $73,458.00 in Stock

August 10, 2026 | marketbeat.com

Entrada Therapeutics (NASDAQ:TRDA) Major Shareholder Ventures L.P. 5Am Sells 10,494 Shares

August 10, 2026 | marketbeat.com

Entrada Therapeutics (NASDAQ:TRDA) Major Shareholder Sells $358,371.45 in Stock

August 10, 2026 | marketbeat.com

Insider Selling: Entrada Therapeutics (NASDAQ:TRDA) Director Sells $358,371.45 in Stock

August 10, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PLRX, RNAC, ALXO, and TRDA Company Descriptions

ALX Oncology NASDAQ:ALXO

$2.03 -0.05 (-2.40%)

As of 09/3/2026 04:00 PM Eastern

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma. It also has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under Phase 1 trial for the treatment of breast cancer and other solid tumors; Quantum Leap Healthcare collaborative with an ADC, fam-trastuzumab deruxtecan-nxki, under Phase 1 trial for the treatment of patients with breast cancer; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; Sanofi with isatuximab and dexamethasone, under Phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma; Academic Gastrointestinal Cancer Consortium with pembrolizumab and cetuximab, under Phase 2 trial to treat refractory microsatellite stable metastatic colorectal cancer; and University of Pittsburgh with liposomal doxorubicin and pembrolizumab, under Phase 2 trial recurrent platinum-resistant ovarian cancer. In addition, the company has collaboration agreement with Tallac Therapeutics, Inc. for the development of ALTA-002, a potent immune activator targeted to myeloid cells in the tumor to promote innate and adaptive anti-cancer immune responses. It also has license agreements with Board of Trustees of the Leland Stanford Junior University, Selexis SA, and Crystal Bioscience, Inc. The company was incorporated in 2015 and is headquartered in South San Francisco, California.

Pliant Therapeutics NASDAQ:PLRX

$1.13 -0.03 (-2.59%)

As of 09/3/2026 04:00 PM Eastern

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.

Cartesian Therapeutics NASDAQ:RNAC

$9.12 +0.04 (+0.44%)

As of 09/3/2026 04:00 PM Eastern

Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases. The company develops Descartes-15 to treat Autoimmune diseases, myeloma; and Descartes-33 which is in preclinical development for treatment of autoimmune diseases. Cartesian Therapeutics, Inc. is headquartered in Gaithersburg, Maryland.

Entrada Therapeutics NASDAQ:TRDA

$7.17 -0.13 (-1.78%)

As of 09/3/2026 04:00 PM Eastern

Entrada Therapeutics, Inc., a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1. The company also offers ENTR-601-45 and ENTR-601-50, which are in preclinical trail for the treatment of Duchenne muscular dystrophy; and ENTR-501, an intracellular thymidine phosphorylase enzyme replacement therapy, which is in preclinical trail for the treatment of mitochondrial neurogastrointestinal encephalomyopathy. Entrada Therapeutics, Inc. has a strategic collaboration and license agreement with Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize ENTR-701. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PLRX, RNAC, ALXO, and TRDA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PLRX, RNAC, ALXO, and TRDA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PLRX, RNAC, ALXO, and TRDA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

PLRX, RNAC, ALXO, and TRDA Company Descriptions

ALX Oncology NASDAQ:ALXO

Pliant Therapeutics NASDAQ:PLRX

Cartesian Therapeutics NASDAQ:RNAC

Entrada Therapeutics NASDAQ:TRDA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PLRX, RNAC, ALXO, and TRDA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PLRX, RNAC, ALXO, and TRDA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PLRX, RNAC, ALXO, and TRDA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

PLRX, RNAC, ALXO, and TRDA Company Descriptions

ALX Oncology NASDAQ:ALXO

Pliant Therapeutics NASDAQ:PLRX

Cartesian Therapeutics NASDAQ:RNAC

Entrada Therapeutics NASDAQ:TRDA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools